Agilent Technologies, Inc.

▲ Bull Case

• ◆CrossLab reaches 50%+ of revenue by FY2027: ACG +9%/yr above base, LDG instruments accelerate with GLP-1 manufacturing tools demand. Market re-rates Agilent to services multiple — $6.50 FY2027E EPS x 27x = $175/share (+46%).
• ◆China QA/QC stabilizes: Validated analytical method regulatory requirements prevent domestic Chinese vendors from displacing Agilent in pharma QA/QC. China revenue floors at ~8-9% and recovers modestly, removing the biggest structural overhang and proving the structural bear case wrong for quality-critical applications.
• ◆BioVectra contributes $300M+ revenue FY2027: Oligonucleotide/siRNA CDMO demand from GLP-1-adjacent gene therapies accelerates faster than expected. BioVectra's scarce manufacturing capacity commands premium pricing, with accretion to non-GAAP EPS from FY2028 onward.

▼ Bear Case

• ◆China structural impairment deepens: Domestic instrument vendors capture QA/QC applications; China falls from ~8-10% to <5% of revenue. Combined with NIH indirect cost cap sustained indefinitely, total revenue headwind of $350-450M vs. base case. Stock re-rates to 20x depressed EPS: ~$99/share (-17.5%).
• ◆Biopharma second destocking: GLP-1 capex pulled forward in FY2026 creates a digestion period in FY2027. Instrument orders stall. CrossLab growth decelerates to 5-6% as new instrument placement slows. FY2027 EPS: $4.50 vs. $5.59 base case.
• ◆BioVectra integration drag extends: CDMO margins remain 15-20% EBITDA dilutive through FY2028 vs. Agilent's 27% blended. Margin expansion stalls at 23-24%. Multiple stays at 20-21x. No re-rating story materializes.

“The central debate: Is the biopharma recovery durable, and can Agilent sustain multiple expansion to 22-25x as it completes? Bulls argue the destocking cycle was a once-in-a-decade event, CrossLab's recurring revenue provides visibility, and GLP-1 drug manufacturing is a multi-year capex cycle that benefits analytical chemistry tools vendors — Agilent has historically traded at 22-25x through recovery phases. Bears argue China structural displacement is not temporary but a permanent share loss driven by government subsidies to domestic vendors, regulatory decoupling, and BIOSECURE Act uncertainty; NIH indirect cost caps, if sustained, create a persistent academic lab funding headwind; and BioVectra is a bet on a niche CDMO market Agilent has no prior operational experience in. Our read: the recovery is real (confirmed by book-to-bill and revenue acceleration) and the structural China bear overstates the displacement in quality-critical validated applications. The thesis is modestly bullish at $120 — not a slam dunk, but the only complete-coverage ticker in this batch that is below PWFV.”

• ◆Q2 FY2026 Earnings (May 2026): Order book momentum and operating margin trend — HIGH magnitude
• ◆FY2026 Annual Guidance Raise: Revenue revised above $7.5B — MEDIUM-HIGH magnitude
• ◆BioVectra Revenue Disclosure in FY2026 10-K: First material contribution signals M&A success — MEDIUM magnitude
• ◆China Order Recovery Signal (Ongoing): Any positive China pharma QA/QC stabilization — MEDIUM magnitude
• ◆NIH Indirect Cost Court Resolution (2026): Removes $100-150M forward revenue headwind — MEDIUM magnitude
• ◆CrossLab Mix Milestone 50%+ of revenue (FY2027): Triggers re-rating to services multiple narrative — HIGH magnitude
• ◆$2B Buyback Completion (FY2026-2027): Confirms capital return confidence — MEDIUM magnitude

• ◆China structural deepens to <6% of revenue (HIGH probability): -$250-350M revenue impact — Geopolitical/Competitive
• ◆NIH indirect cost cap sustained indefinitely (HIGH probability): -$100-150M academic demand impact — Regulatory
• ◆Biopharma second destocking / GLP-1 digestion in FY2027 (MEDIUM probability): -$280-320M vs. FY2027 base — Cycle
• ◆BioVectra integration fails or remains dilutive (MEDIUM probability): Margin drag through FY2028; no revenue impact if operational — M&A/Execution
• ◆Thermo Fisher CMD competition intensifies (MEDIUM probability): -50-100bps market share in high-end LC/MS — Competitive
• ◆Supply chain tariff cost inflation (LOW-MEDIUM probability): -25-50bps gross margin — Macro